화학요법 치료제 시장 : 인사이트, 경쟁 구도 및 시장 예측(2030년)

Chemotherapy Drugs Market By Drug Class (Alkylating Agents, Mitotic Inhibitors, Antimetabolites, Topoisomerase Inhibitors, And Others), By Indication (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, And Others), By Route Of Administration (Oral And Parenteral), by geography is estimated to register growth at a remarkable CAGR forecast during 2024-2030 owing to increasing prevalence of different cancer types and increasing pharmaceutical trials for chemotherapy drugs

The global chemotherapy drugs market is estimated to grow at a CAGR of 8.65% during the forecast period 2024-2030. The chemotherapy drugs market is slated to witness prosperity owing to factors such as the growing prevalence of various cancer coupled with the increasing number of risk factors associated with cancer development, increasing pharmaceutical trials for chemotherapy drugs, and the growing focus on improving the safety and efficacy of chemotherapy drugs are further expected to result in the appreciable revenue growth in the chemotherapy drugs market during the forecast period (2024-2030).

Chemotherapy Drugs Market Dynamics:

The rising prevalence of different cancer types such as breast cancer, lung cancer, blood cancer, and others turns out to be the major factor for accelerating the chemotherapy drugs market. For instance, according to the data cited by the World Health Organization 2022, worldwide around 2.26 million cases of breast, 2.21 million cases of lung, 1.93 million cases of colon and rectum, 1.41 million cases of prostate, and 1.09 million cases of stomach cancer were reported in 2020. Also, as per the Global Cancer Observatory 2022 data, globally around 544,352 cases of Non-Hodgkin lymphoma and 83,087 cases of Hodgkin lymphoma were reported in 2020. As per the same source globally around 474,519 leukemia cases and nearly 176,404 cases of multiple myeloma were reported in 2020. Chemotherapy drugs belonging to different drug classes such as alkylating agents, antimetabolites, anti-tumor antibiotics, and others are widely utilized in the treatment and management of different cancer.

Another key factor responsible for the growth of the chemotherapy drugs market is the continuous rise in the risk factors associated with the development of cancers including tobacco consumption, smoking, family history, previous cancer treatment, and others. According to WHO 2022, it was recorded that around 22.3% of the global population was involved in tobacco consumption. Tobacco-based products such as cigarettes and cigars are one of the major risk factors for cancers. The increasing rate of the smoking population in multiple countries around the world increases the overall burden of cancer development. For instance, as per the Nanny State Index (NSI) 2022, the rate of people smoking in Austria was 26.40% in 2020. As per the data reported by Foundation for a Smoke-Free World 2022, there were 20.4 million adult smokers in Brazil in 2019.

The increasing number of approval and launches for chemotherapy drugs is going to be beneficial for the growth of the chemotherapy drugs market. For example, in April 2022, BDR Pharmaceuticals announced the launch of an anti-cancer drug named Furmecil for the treatment of gastric cancer.

However, side-effects associated with chemotherapy drugs and the occurrence of drug resistance in chemotherapy may act as restraining factors to the chemotherapy drugs market growth.

The chemotherapy drugs market reported a short period of restraint in the market growth due to the implementation of the lockdown as a necessary step to stop the spread of COVID-19 infection. Owing to the shortage of raw materials, R&D and manufacturing of chemotherapy drugs were affected. The import and export of chemotherapy drugs were also hampered due to border closures. Also, the oncology departments in hospitals and various oncology-based clinics were closed down due to shifted primary focus on treating patients suffering from COVID- 19 which in turn led to the decline in diagnosis and treatment of cancer patients, ultimately slowing the chemotherapy drugs market growth for a while. However, with the resumption of activities across industries including the healthcare and pharmaceutical sector, there has been a rising demand for chemotherapy drugs during the forecast period from 2024-2030.

Chemotherapy Drugs Market Segment Analysis:

Chemotherapy Drugs Market by Drug Class (Alkylating Agents, Mitotic Inhibitors, Antimetabolites, Topoisomerase Inhibitors, and Others], Indication (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, and Others), Route of Administration (Parenteral, and Oral), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Based on the indication segment of the chemotherapy drugs market, the lung cancer category is projected to register a significant growth in revenue in the chemotherapy drugs market during the forecast period (2024-2030).

This can be ascribed to the increasing prevalence of lung cancer and increasing chemotherapy drug research and development activities for lung cancer. As per the Global Cancer Observatory 2020, globally around 19.3 million lung cancer cases were diagnosed in 2020. The source further stated that by 2040, about 28.9 million new cases of lung cancer will be diagnosed across the world.

Additionally, the rising number of pharmaceutical trials of chemotherapy drugs for lung cancer may assist in the growing demand for chemotherapy drugs. For example, Incyte Corporation is currently conducting a Phase III clinical trial for assessing the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metastatic squamous and nonsquamous non-small cell lung cancer (NSCLC), and the trial is estimated to get complete by August 2025.

Therefore, considering the rising prevalence of lung cancer and the increasing focus of companies on developing and launching new chemotherapy drugs for lung cancer, the indication category is expected to generate considerable revenue thereby pushing the overall growth of global chemotherapy drugs during the forecast period.

North America is expected to dominate the overall Chemotherapy Drugs Market:

Among all the regions, North America is expected to lead in revenue generation in the global chemotherapy drugs market. This can be ascribed to the presence of a large patient pool associated with cancer, an increase in the number of smokers, and a highly potent market in terms of product development and launches, high consumer awareness, and the local presence of key market players among other factors in the region.

One of the prominent factors supporting the growth of the North America cancer diagnostic market is the rising prevalence of cancer. As per the figures mentioned by the American Cancer Society 2022, it was estimated that around 1.9 million new cancer cases were diagnosed in the United States in 2022. Also, according to the data provided by the Centers for Disease Control and Prevention (CDC) in 2022, around 1,752,735 new cases of cancer were reported in the US in 2019. As per Globocan 2022 data, there were around 61,152 new cases of leukemia recorded in 2020 in the United States. As per the same source around 73, 652 cases of Non-Hodgkin lymphoma and 8,107 new cases of Hodgkin lymphoma were recorded in 2020 in the US.

Another factor contributing to the growth of the chemotherapy drugs market is the continued rise in the number of individuals involved in smoking. For instance, as per the Centers for Disease Control and Prevention 2022, approximately 40 million people smoke cigarettes in the US. As per the same source, every day nearly 1,600 US youth aged 18 years or younger smoke their first cigarette. Smoking affects both smokers and non-smokers eventually increasing their risk for cancer such as lung, oral, and blood cancer, and others.

Therefore, owing to the above-mentioned factors, the chemotherapy drugs market is expected to bolster in the United States during the forecast period.

Chemotherapy Drugs Market Key Players:

Some of the key market players operating in the chemotherapy drugs market include Johnson & Johnson Services Inc., Pfizer Inc., GlaxoSmithKline PLC, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Novartis AG, Merck & Co. Inc., Sanofi S.A., Celgene Corporation, Bristol-Myers Squibb Company, AbbVie Inc., Amgen, Loxo Oncology Inc., AstraZeneca PLC, Astellas Pharma Inc., GLS Pharma Pvt. Ltd., TAIHO PHARMA CANADA, INC., Beta Drugs, TAIHO PHARMA CANADA, INC., Ipsen Pharma, Aurobindo Pharma, and others.

Recent Developmental Activities in the Chemotherapy Drugs Market:

In June 2020, the US Food and Administration approved two new drugs, namely olaparib (Lynparza) and rucaparib (Rubraca) for the treatment of prostate cancer.

In May 2020, FDA approved the encorafenib (Braftovi) drug for the treatment of some patients suffering from colorectal cancer.

In October 2022, (Verzenio) abemaciclib was approved by US FDA as the first and only CDK 4/6 inhibitor for some people suffering from the risk of HR+ HER2- High-Risk Early Breast Cancer.

Key Takeaways from the Chemotherapy Drugs Market Report Study

Market size analysis for current chemotherapy drugs market size (2023), and market forecast for 5 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the chemotherapy drugs market.

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global chemotherapy drugs market.

Various opportunities available for the other competitor in the chemotherapy drugs market space.

What are the top-performing segments in 2023? How these segments will perform in 2027?

Which are the top-performing regions and countries in the current chemotherapy drugs market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for chemotherapy drugs market growth in the coming future?

Target Audience who can be benefited from this Chemotherapy Drugs Market Report Study

Chemotherapy drugs providers

Research organizations and consulting companies

Chemotherapy drugs -related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in chemotherapy drugs.

Various end users who want to know more about the chemotherapy drugs market and the latest developments in the chemotherapy drugs market.

Frequently Asked Questions for the Chemotherapy Drugs Market:

1. What are chemotherapy drugs?

Chemotherapy drugs belonging to different drug classes such as mitotic inhibitors, alkylating agents, antimetabolites, topoisomerase inhibitors, and others are intended for killing cancer cells.

2. What is the market for global chemotherapy drugs?

The global chemotherapy drugs market is estimated to grow at a CAGR of 8.65% during the forecast period 2024-2030.

3. What are the drivers for the global chemotherapy drugs market?

The chemotherapy drugs market is slated to witness prosperity owing to factors such as the growing prevalence of different cancer types, the rising number of risk factors for cancer, the increasing number of pharmaceutical trials coupled with increasing approval and launches for chemotherapy drugs, and the growing focus on improving the safety, efficacy, and affordability of chemotherapy drugs are further expected to result in the appreciable revenue growth in the chemotherapy drugs market during the forecast period (2024-2030).

4. Who are the key players operating in the global chemotherapy drugs market?

Some of the key market players operating in the global chemotherapy drugs market include Johnson & Johnson Services Inc., Pfizer Inc., GlaxoSmithKline PLC, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Novartis AG, Merck & Co. Inc., Sanofi S.A., Celgene Corporation, Bristol-Myers Squibb Company, AbbVie Inc., Amgen, Loxo Oncology Inc., AstraZeneca PLC, Astellas Pharma Inc., GLS Pharma Pvt. Ltd., TAIHO PHARMA CANADA, INC., Beta Drugs, TAIHO PHARMA CANADA, INC., Ipsen Pharma, Aurobindo Pharma, and others.

5. Which region has the highest share in the chemotherapy drugs market?

North America is expected to dominate the overall chemotherapy drugs market during the forecast period, 2022 to 2027. This can be ascribed to the presence of a large patient pool associated with cancer, a rise in several smokers, high-tech medical facilities, government initiatives, a highly potent market in terms of product development and launches, and the local presence of key market players among other factors in the region.

Table of Contents

1.Chemotherapy Drugs Report Introduction

2. Chemotherapy Drugs Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment

3. Chemotherapy Drugs Key Factors Analysis

• 3.1. Chemotherapy Drugs Market Drivers
  • 3.1.1. Rising prevalence of various cancer
  • 3.1.2. Increasing risk factors for cancer
  • 3.1.3. Increasing pharmaceutical trials for chemotherapy drugs
• 3.2. Chemotherapy Drugs Market Restraints and Challenges
  • 3.2.1. Side effects associated with chemotherapy
  • 3.2.2. Drug Resistance in chemotherapy
• 3.3. Chemotherapy Drugs Market Opportunities
  • 3.3.1. Advances in lipid-based nanoparticles for cancer chemotherapy
  • 3.3.2. Exploring the effect of chemotherapy drugs on immune system disorders

4. Chemotherapy Drugs Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

5. COVID-19 Impact Analysis on Chemotherapy Drugs Market

6. Chemotherapy Drugs Market Layout

• 6.1. By Drug Class
  • 6.1.1. Alkylating Agents
  • 6.1.2. Mitotic Inhibitors
  • 6.1.3. Antimetabolites
  • 6.1.4. Topoisomerase Inhibitors
  • 6.1.5. Others
• 6.2. By Indication
  • 6.2.1. Lung Cancer
  • 6.2.2. Breast Cancer
  • 6.2.3. Prostate Cancer
  • 6.2.4. Colorectal Cancer
  • 6.2.5. Others
• 6.3. By Route of Administration
  • 6.3.1. Oral
  • 6.3.2. Parenteral
• 6.4. By Geography
  • 6.4.1. North America
    • 6.4.1.1. United States Chemotherapy Drugs Market in USD million (2021-2030)
    • 6.4.1.2. Canada Chemotherapy Drugs Market in USD million (2021-2030)
    • 6.4.1.3. Mexico Chemotherapy Drugs Market in USD million (2021-2030)
  • 6.4.2. Europe
    • 6.4.2.1. France Chemotherapy Drugs Market in USD million (2021-2030)
    • 6.4.2.2. Germany Chemotherapy Drugs Market in USD million (2021-2030)
    • 6.4.2.3. United Kingdom Chemotherapy Drugs Market in USD million (2021-2030)
    • 6.4.2.4. Italy Chemotherapy Drugs Market in USD million (2021-2030)
    • 6.4.2.5. Spain Chemotherapy Drugs Market in USD million (2021-2030)
    • 6.4.2.6. Rest of Europe Chemotherapy Drugs Market in USD million (2021-2030)
  • 6.4.3. Asia-Pacific
    • 6.4.3.1. China Chemotherapy Drugs Market in USD million (2021-2030)
    • 6.4.3.2. Japan Chemotherapy Drugs Market in USD million (2021-2030)
    • 6.4.3.3. India Chemotherapy Drugs Market in USD million (2021-2030)
    • 6.4.3.4. Australia Chemotherapy Drugs Market in USD million (2021-2030)
    • 6.4.3.5. South Korea Chemotherapy Drugs Market in USD million (2021-2030)
    • 6.4.3.6. Rest of Asia Pacific Chemotherapy Drugs Market in USD million (2021-2030)
  • 6.4.4. Rest of the World (RoW)
    • 6.4.4.1. Middle East Chemotherapy Drugs Market in USD million (2021-2030)
    • 6.4.4.2. Africa Chemotherapy Drugs Market in USD million (2021-2030)
    • 6.4.4.3. South America Chemotherapy Drugs Market in USD million (2021-2030)

7. Chemotherapy Drugs Market Company and Product Profiles

• 7.1. Pfizer Inc.
  • 7.1.1. Company Overview
  • 7.1.2. Company Snapshot
  • 7.1.3. Financial Overview
  • 7.1.4. Product Listing
  • 7.1.5. Entropy
• 7.2. Johnson & Johnson Services Inc.
  • 7.2.1. Company Overview
  • 7.2.2. Company Snapshot
  • 7.2.3. Financial Overview
  • 7.2.4. Product Listing
  • 7.2.5. Entropy
• 7.3. GlaxoSmithKline PLC
  • 7.3.1. Company Overview
  • 7.3.2. Company Snapshot
  • 7.3.3. Financial Overview
  • 7.3.4. Product Listing
  • 7.3.5. Entropy
• 7.4. Eli Lilly and Company
  • 7.4.1. Company Overview
  • 7.4.2. Company Snapshot
  • 7.4.3. Financial Overview
  • 7.4.4. Product Listing
  • 7.4.5. Entropy
• 7.5. F. Hoffmann-La Roche Ltd
  • 7.5.1. Company Overview
  • 7.5.2. Company Snapshot
  • 7.5.3. Financial Overview
  • 7.5.4. Product Listing
  • 7.5.5. Entropy
• 7.6. Novartis AG
  • 7.6.1. Company Overview
  • 7.6.2. Company Snapshot
  • 7.6.3. Financial Overview
  • 7.6.4. Product Listing
  • 7.6.5. Entropy
• 7.7. Merck & Co. Inc.
  • 7.7.1. Company Overview
  • 7.7.2. Company Snapshot
  • 7.7.4. Financial Overview
  • 7.7.4. Product Listing
  • 7.7.5. Entropy
• 7.8. Sanofi S.A.
  • 7.8.1. Company Overview
  • 7.8.2. Company Snapshot
  • 7.8.3. Financial Overview
  • 7.8.4. Product Listing
  • 7.8.5. Entropy
• 7.9. Celgene Corporation
  • 7.9.1. Company Overview
  • 7.9.2. Company Snapshot
  • 7.9.3. Financial Overview
  • 7.9.4. Product Listing
  • 7.9.5. Entropy
• 7.10. Bristol-Myers Squibb Company
  • 7.10.1. Company Overview
  • 7.10.2. Company Snapshot
  • 7.10.3. Financial Overview
  • 7.10.4. Product Listing
  • 7.10.5. Entropy
• 7.11. AbbVie Inc.
  • 7.11.1. Company Overview
  • 7.11.2. Company Snapshot
  • 7.11.3. Financial Overview
  • 7.11.4. Product Listing
  • 7.11.5. Entropy
• 7.12. Amgen
  • 7.12.1. Company Overview
  • 7.12.2. Company Snapshot
  • 7.12.3. Financial Overview
  • 7.12.4. Product Listing
  • 7.12.5. Entropy
• 7.13. Astellas Pharma Inc.
  • 7.13.1. Company Overview
  • 7.13.2. Company Snapshot
  • 7.13.3. Financial Overview
  • 7.13.4. Product Listing
  • 7.13.5. Entropy
• 7.14. AstraZeneca PLC
  • 7.14.1. Company Overview
  • 7.14.2. Company Snapshot
  • 7.14.3. Financial Overview
  • 7.14.4. Product Listing
  • 7.14.5. Entropy
• 7.15. Loxo Oncology Inc.
  • 7.15.1. Company Overview
  • 7.15.2. Company Snapshot
  • 7.15.3. Financial Overview
  • 7.15.4. Product Listing
  • 7.15.5. Entropy
• 7.16. GLS Pharma Pvt. Ltd.
  • 7.16.1. Company Overview
  • 7.16.2. Company Snapshot
  • 7.16.3. Financial Overview
  • 7.16.4. Product Listing
  • 7.16.5. Entropy
• 7.17. Beta Drugs
  • 7.17.1. Company Overview
  • 7.17.2. Company Snapshot
  • 7.17.3. Financial Overview
  • 7.17.4. Product Listing
  • 7.17.5. Entropy
• 7.18. TAIHO PHARMA CANADA, INC.
  • 7.18.1. Company Overview
  • 7.18.2. Company Snapshot
  • 7.18.3. Financial Overview
  • 7.18.4. Product Listing
  • 7.18.5. Entropy
• 7.19. Ipsen Pharma
  • 7.19.1. Company Overview
  • 7.19.2. Company Snapshot
  • 7.19.3. Financial Overview
  • 7.19.4. Product Listing
  • 7.19.5. Entropy
• 7.20. Aurobindo Pharma
  • 7.20.1. Company Overview
  • 7.20.2. Company Snapshot
  • 7.20.3. Financial Overview
  • 7.20.4. Product Listing
  • 7.20.5. Entropy

8. KOL Views

9. Project Approach

10. About DelveInsight

11. Disclaimer & Contact Us